Section Arrow
ALLK.NASDAQ
- Allakos
Quotes are at least 15-min delayed:2025/01/11 11:23 EST
Last
 0.9688
-0.0104 (-1.06%)
Day High 
0.9796 
Prev. Close
0.9792 
1-M High
1.38 
Volume 
153.30K 
Bid
0.9303
Ask
0.9852
Day Low
0.94 
Open
0.9569 
1-M Low
0.9306 
Market Cap 
87.49M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.17 
20-SMA 1.15 
50-SMA 1.15 
52-W High 1.69 
52-W Low 0.535 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.03/-1.59
Enterprise Value
125.70M
Balance Sheet
Book Value Per Share
0.81
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 11:23 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.